Acadia Pharmaceuticals (NASDAQ:ACAD) shares have crossed bullishly above their 10-day moving average of $36.39 on a volume of 615K shares. This may provide short-term investors a chance for a long position, as such a crossover often suggests higher prices in the near term.
Acadia Pharmaceuticals (NASDAQ:ACAD) has potential upside of 17.0% based on a current price of $36.62 and analysts' consensus price target of $42.86. Acadia Pharmaceuticals shares have support at the 50-day moving average (MA) of $36.18 and additional support at the 200-day MA of $29.95.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
Acadia Pharmaceuticals share prices have moved between a 52-week high of $46.48 and a 52-week low of $17.15 and are now trading 114% above that low price at $36.62 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has declined 0.2%.